{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:25:55Z","timestamp":1780680355466,"version":"3.54.1"},"reference-count":157,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32 DK083251"],"award-info":[{"award-number":["T32 DK083251"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK125293"],"award-info":[{"award-number":["R01 DK125293"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01 AI141350"],"award-info":[{"award-number":["P01 AI141350"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM007250"],"award-info":[{"award-number":["T32 GM007250"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pharmr.2026.100132","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:46:38Z","timestamp":1773967598000},"page":"100132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging mechanistic trends and clinical efficacy for methotrexate: Applications to inflammatory bowel disease"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-022X","authenticated-orcid":false,"given":"Jeehyun Karen","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-915X","authenticated-orcid":false,"given":"Theresa T.","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-0231","authenticated-orcid":false,"given":"Tommaso L.","family":"Parigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.pharmr.2026.100132_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100132_bib2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/art.27434","article-title":"Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations","volume":"62","author":"Becker","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100132_bib5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/14782715241312256","article-title":"Low-dose methotrexate in Rheumatology: a reinvented drug","volume":"55","author":"Gupta","year":"2025","journal-title":"J R Coll Physicians Edinb"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/jps.2600670434","article-title":"Drug absorption VIII: kinetics of GI absorption of methotrexate","volume":"67","author":"Chungi","year":"1978","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib10","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/0006-2952(92)90316-B","article-title":"Methotrexate transport in the human intestine. Evidence for heterogeneity","volume":"43","author":"Zimmerman","year":"1992","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2036.1997.00175.x","article-title":"The absorption of low-dose methotrexate in patients with inflammatory bowel disease","volume":"11","author":"Moshkowitz","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-9236(99)70119-0","article-title":"Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease","volume":"65","author":"Egan","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197803010-00001","article-title":"Clinical pharmacokinetics of methotrexate","volume":"3","author":"Shen","year":"1978","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0006-2952(72)90125-6","article-title":"Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid","volume":"21","author":"Valerino","year":"1972","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0022-3565(24)39150-5","article-title":"Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid","volume":"294","author":"Widemann","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"3907","key":"10.1016\/j.pharmr.2026.100132_bib17","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1126\/science.166.3907.887","article-title":"Antibiotics alter methotrexate metabolism and excretion","volume":"166","author":"Zaharko","year":"1969","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100132_bib19","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood.2024026211","article-title":"Glucarpidase for treatment of high-dose methotrexate toxicity","volume":"145","author":"Gupta","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0163-7258(85)90083-X","article-title":"The cellular pharmacology of methotrexate","volume":"28","author":"Goldman","year":"1985","journal-title":"Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100132_bib21","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/0006-2952(87)90216-4","article-title":"Transport of folate compounds by leukemic cells. Evidence for a single influx carrier for methotrexate, 5-methyltetrahydrofolate, and folate in CCRF-CEM human lymphoblasts","volume":"36","author":"Henderson","year":"1987","journal-title":"Biochem Pharmacol"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100132_bib22","first-page":"7225","article-title":"Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport","volume":"61","author":"Zeng","year":"2001","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11926-010-0120-3","article-title":"Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?","volume":"12","author":"Danila","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.pharmr.2026.100132_bib24","series-title":"Compendium of Inflammatory Diseases","first-page":"934","article-title":"Methotrexate","author":"Pile","year":"2016"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib25","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100132_bib26","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.24653","article-title":"Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment","volume":"60","author":"Stamp","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17512433.2024.2416674","article-title":"Methotrexate polyglutamates","volume":"17","author":"Yang","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100132_bib28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/pgs.11.86","article-title":"Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases","volume":"12","author":"Stamp","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0014-4827(69)90039-1","article-title":"Studies on in vitro lymphocyte proliferation in cultures synchronized by the inhibition of DNA synthesis. I. Variability of S plus G2 periods of first generation cells","volume":"56","author":"Steffen","year":"1969","journal-title":"Exp Cell Res"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100132_bib31","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2015-208736","article-title":"Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase\/p53 axis","volume":"75","author":"Municio","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib32","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100132_bib33","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","article-title":"Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates","volume":"82","author":"Allegra","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib34","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1007\/s11033-020-05481-9","article-title":"Molecular mechanism of action and pharmacokinetic properties of methotrexate","volume":"47","author":"Maksimovic","year":"2020","journal-title":"Mol Biol Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.pharmr.2026.100132_bib36","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fimmu.2020.01310","article-title":"Inflammatory bowel diseases: it\u2019s time for the adenosine system","volume":"11","author":"Antonioli","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib37","doi-asserted-by":"crossref","first-page":"30824","DOI":"10.1038\/srep30824","article-title":"MicroRNA-16 is putatively involved in the NF-\u03baB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting","volume":"6","author":"Tian","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100132_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1429736","article-title":"Adenosine-mediated immune responses in inflammatory bowel disease","volume":"12","author":"Vuerich","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00054725-199908000-00004","article-title":"Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate","volume":"5","author":"Egan","year":"1999","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100132_bib40","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","article-title":"Methotrexate and BAFF interaction prevents immunization against TNF inhibitors","volume":"77","author":"Bitoun","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00281-024-01035-4","article-title":"Role of polyamines in intestinal mucosal barrier function","volume":"47","author":"Nakamura","year":"2025","journal-title":"Semin Immunopathol"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100132_bib42","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.3390\/ijms22179546","article-title":"The role of the BH4 cofactor in nitric oxide synthase activity and cancer progression: two sides of the same coin","volume":"22","author":"Gon\u00e7alves","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib43","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/molecules28114414","article-title":"Nitric oxide synthases in rheumatoid arthritis","volume":"28","author":"Huang","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2567.2004.01984.x","article-title":"Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle","volume":"113","author":"Kolios","year":"2004","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00054725-200305000-00006","article-title":"Nitric oxide in inflammatory bowel disease","volume":"9","author":"Cross","year":"2003","journal-title":"Inflam Bowel Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib46","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1002\/art.38805","article-title":"Methotrexate inhibits NF-\u03baB activity via long intergenic (noncoding) RNA-p21 induction","volume":"66","author":"Spurlock","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13578-020-00445-9","article-title":"An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer","volume":"10","author":"Amirinejad","year":"2020","journal-title":"Cell Biosci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbad031","article-title":"The significance of long non-coding RNAs in the pathogenesis, diagnosis and treatment of inflammatory bowel disease","volume":"6","author":"Jiang","year":"2023","journal-title":"Precis Clin Med"},{"key":"10.1016\/j.pharmr.2026.100132_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116868","article-title":"Long non-coding RNAs as pathophysiological regulators, therapeutic targets and novel extracellular vesicle biomarkers for the diagnosis of inflammatory bowel disease","volume":"176","author":"Heydari","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100132_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164778","article-title":"TAp63, a methotrexate target in CD4+ T cells, suppresses Foxp3 expression and exacerbates autoimmune arthritis","volume":"8","author":"Suga","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13075-024-03403-9","article-title":"Low dose methotrexate impaired T cell transmigration through down-regulating CXCR4 expression in rheumatoid arthritis (RA)","volume":"26","author":"Ding","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100132_bib52","first-page":"4655","article-title":"Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29","volume":"52","author":"Dahiya","year":"1992","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1242\/jcs.106.3.771","article-title":"Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations","volume":"106","author":"Lesuffleur","year":"1993","journal-title":"J Cell Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100132_bib54","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1136\/gut.35.10.1449","article-title":"Adhesion of human enterotoxigenic Escherichia coli to human mucus secreting HT-29 cell subpopulations in culture","volume":"35","author":"Kerneis","year":"1994","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100132_bib55","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1128\/aem.59.12.4121-4128.1993","article-title":"Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions","volume":"59","author":"Bernet","year":"1993","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib56","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI108199","article-title":"Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion","volume":"56","author":"Myers","year":"1975","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cell.2021.12.024","article-title":"GSDMB is increased in IBD and regulates epithelial restitution\/repair independent of pyroptosis","volume":"185","author":"Rana","year":"2022","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100132_bib58","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.addr.2010.11.001","article-title":"Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis","volume":"63","author":"Zhao","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib60","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/gut.21.6.486","article-title":"Response of the rat small-intestine epithelium to methotrexate","volume":"21","author":"Taminiau","year":"1980","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2131\/jts.39.319","article-title":"Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis","volume":"39","author":"Ohbayashi","year":"2014","journal-title":"J Toxicol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib62","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00408-016-9935-7","article-title":"Methotrexate-induced epithelial-mesenchymal transition in the alveolar epithelial cell line A549","volume":"194","author":"Kawami","year":"2016","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bbrc.2018.02.111","article-title":"Folic acid prevents methotrexate-induced epithelial-mesenchymal transition via suppression of secreted factors from the human alveolar epithelial cell line A549","volume":"497","author":"Kawami","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmr.2026.100132_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.737570","article-title":"Epithelial-to-mesenchymal transition in fibrosis: concepts and targeting strategies","volume":"12","author":"Lovisa","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.chom.2020.12.008","article-title":"Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation","volume":"29","author":"Nayak","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pharmr.2026.100132_bib66","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ebiom.2018.06.029","article-title":"Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota","volume":"33","author":"Zhou","year":"2018","journal-title":"EBiomedicine"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ncprheum0380","article-title":"Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs\u2014from bench to bedside","volume":"3","author":"van der Heijden","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.pharmr.2026.100132_bib68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13000-015-0447-1","article-title":"MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients","volume":"10","author":"Micsik","year":"2015","journal-title":"Diagn Pathol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10787-018-0459-z","article-title":"Predicting methotrexate resistance in rheumatoid arthritis patients","volume":"26","author":"Yu","year":"2018","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib71","first-page":"27","article-title":"Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis","volume":"21","author":"Stranzl","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib72","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00008571-200411000-00004","article-title":"Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis","volume":"14","author":"Dervieux","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib73","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/art.21573","article-title":"Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis","volume":"54","author":"Weisman","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib74","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/art.21726","article-title":"Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes","volume":"54","author":"Wessels","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-110-5-353","article-title":"Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease","volume":"110","author":"Kozarek","year":"1989","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib76","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.pharmr.2026.100132_bib77","first-page":"1724","article-title":"Methotrexate in Crohn\u2019s disease: results of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Arora","year":"1999","journal-title":"Hepatogastroenterology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100132_bib78","first-page":"2203","article-title":"Methotrexate in chronic active Crohn\u2019s disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib79","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100132_bib80","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. North American Crohn\u2019s Study Group investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042737-200601000-00003","article-title":"Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn\u2019s disease: a controlled pilot study","volume":"18","author":"Schr\u00f6der","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2026.100132_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100271","article-title":"Efficacy and safety of methotrexate in the management of inflammatory bowel disease: a systematic review and meta-analysis of randomized, controlled trials","volume":"20","author":"Nielsen","year":"2020","journal-title":"EClinicalmedicine"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100132_bib83","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn\u2019s disease: a randomised, investigator-blind study","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib84","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib85","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib86","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100132_bib87","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib88","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib89","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the Aspire trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib90","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2014.01.040","article-title":"Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?","volume":"146","author":"Narula","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib91","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2036.2010.04569.x","article-title":"Mucosal healing with methotrexate in Crohn\u2019s disease: a prospective comparative study with azathioprine and infliximab","volume":"33","author":"Laharie","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100132_bib92","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100132_bib93","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib94","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.18194","article-title":"Systematic review: methotrexate-A poorly understood and underused medication in inflammatory bowel disease","volume":"60","author":"Sequier","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib95","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ecco-jcc\/jjz148","article-title":"Longitudinal trajectory of fatigue with initiation of biologic therapy in inflammatory bowel diseases: a prospective cohort study","volume":"14","author":"Borren","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100132_bib96","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.3390\/jcm12134382","article-title":"The role of low-dose oral methotrexate in increasing anti-TNF drug levels and reducing immunogenicity in IBD","volume":"12","author":"Demase","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib97","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial","volume":"110","author":"Oren","year":"1996","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib98","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","article-title":"Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis","volume":"150","author":"Carbonnel","year":"2016","journal-title":"Gastroenterology"},{"issue":"suppl 3","key":"10.1016\/j.pharmr.2026.100132_bib99","first-page":"A75","article-title":"Low-dose weekly methotrexate therapy in remission maintenance in ulcerative colitis","volume":"39","author":"Onuk","year":"1996","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib100","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2018.06.046","article-title":"Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis","volume":"155","author":"Herfarth","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100132_bib101","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/ibd.21246","article-title":"Efficacy of methotrexate in ulcerative colitis: failure or promise","volume":"16","author":"Herfarth","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib102","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/MIB.0b013e31828133e8","article-title":"Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System","volume":"19","author":"Khan","year":"2013","journal-title":"Inflam Bowel Dis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib103","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cgh.2012.12.026","article-title":"Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn\u2019s disease","volume":"11","author":"Seinen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib104","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/apt.16039","article-title":"Thiopurines vs methotrexate: comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease","volume":"52","author":"Vasudevan","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ibd.21820","article-title":"Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials","volume":"18","author":"Khan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib106","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2023.02.018","article-title":"Methotrexate-induced liver fibrosis: the end of a long-held belief","volume":"78","author":"Di Martino","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib107","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41584-022-00883-4","article-title":"Busting the myth of methotrexate chronic hepatotoxicity","volume":"19","author":"Di Martino","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.dld.2011.09.015","article-title":"The use of methotrexate for treatment of inflammatory bowel disease in clinical practice","volume":"44","author":"Saibeni","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib109","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.clnu.2022.12.004","article-title":"ESPEN guideline on Clinical Nutrition in inflammatory bowel disease","volume":"42","author":"Bischoff","year":"2023","journal-title":"Clin Nutr"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib110","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib111","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100132_bib112","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"K\u00f6ller","year":"2009","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib113","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jgh.12015","article-title":"Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review","volume":"28","author":"Subramaniam","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.gastro.2013.09.035","article-title":"Lymphoma: the b\u00eate noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100132_bib116","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/MIB.0000000000000102","article-title":"Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn\u2019s disease","volume":"20","author":"Sunseri","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.gastro.2006.04.049","article-title":"American Gastroenterological Association institute technical review on the use of gastrointestinal medications in pregnancy","volume":"131","author":"Mahadevan","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib118","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/rheumatology\/ket390","article-title":"No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study","volume":"53","author":"Weber-Schoendorfer","year":"2014","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100132_bib119","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.jid.2017.03.030","article-title":"Birth outcomes in children fathered by men treated with immunosuppressant drugs before conception-A Danish population-based cohort study","volume":"137","author":"Egeberg","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/MIB.0000000000001064","article-title":"The influence of methotrexate treatment on male fertility and pregnancy outcome after paternal exposure","volume":"23","author":"Grosen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100132_bib121","first-page":"1356","article-title":"Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?","volume":"15","author":"Ahern","year":"1988","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib122","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00278469","article-title":"The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis","volume":"42","author":"Tracy","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100132_bib123","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/03009748909101471","article-title":"Drug interactions with non steroidal anti-inflammatory drugs (NSAIDs)","volume":"83","author":"Weinblatt","year":"1989","journal-title":"Scand J Rheumatol Suppl"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib124","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/clpt.1990.69","article-title":"Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis","volume":"47","author":"Stewart","year":"1990","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib125","first-page":"2072","article-title":"The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg","volume":"22","author":"Kremer","year":"1995","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib126","first-page":"41","article-title":"Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months","volume":"22","author":"Kremer","year":"1995","journal-title":"J Rheumatol"},{"issue":"6120","key":"10.1016\/j.pharmr.2026.100132_bib127","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bmj.1.6120.1097","article-title":"Prolongation and enhancement of serum methotrexate concentrations by probenecid","volume":"1","author":"Aherne","year":"1978","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib128","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","article-title":"Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors","volume":"17","author":"Bezabeh","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00686028","article-title":"Impact of omeprazole on the plasma clearance of methotrexate","volume":"33","author":"Reid","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02549529","article-title":"A double-blind placebo-controlled trial of omeprazole on urinary pH in healthy subjects","volume":"24","author":"Osther","year":"1992","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib131","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.ki.5002645","article-title":"The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane","volume":"73","author":"Huls","year":"2008","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib132","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1060028016672035","article-title":"Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors","volume":"51","author":"Hall","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib133","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jcpt.12060","article-title":"Methotrexate and trimethoprim\u2013sulphamethoxazole: extremely serious and life-threatening combination","volume":"38","author":"Al-Quteimat","year":"2013","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib134","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1586\/ecp.11.57","article-title":"Pharmacokinetic drug-drug interactions with methotrexate in oncology","volume":"4","author":"Lev\u00eaque","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3899\/jrheum.090153","article-title":"Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review","volume":"37","author":"Bourr\u00e9-Tessier","year":"2010","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib136","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/bcp.16017","article-title":"Genetic biomarkers of methotrexate response and safety in Crohn\u2019s disease: data from the Spanish ENEIDA registry","volume":"90","author":"Salazar","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib137","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41397-018-0047-z","article-title":"Genetic markers in methotrexate treatments","volume":"18","author":"Giletti","year":"2018","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib138","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib139","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/mgme.2000.3034","article-title":"A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia","volume":"70","author":"Chango","year":"2000","journal-title":"Mol Genet Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100132_bib140","first-page":"3416","article-title":"Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G\/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers","volume":"7","author":"Whetstine","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib141","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/tpj.2012.7","article-title":"Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients","volume":"13","author":"Owen","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib142","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/pgs.14.25","article-title":"Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update","volume":"15","author":"Zhu","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100132_bib143","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/apt.16315","article-title":"Effectiveness and safety of methotrexate monotherapy in patients with Crohn\u2019s disease refractory to Anti-TNF-\u03b1: results from the ENEIDA registry","volume":"53","author":"Mesonero","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100132_bib144","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (Explorer)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","article-title":"Natural disease course of Crohn\u2019s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study","volume":"68","author":"Burisch","year":"2019","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100132_bib146","first-page":"481","article-title":"Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis","volume":"33","author":"Hoekstra","year":"2006","journal-title":"J Rheumatol"},{"issue":"11\u201312","key":"10.1016\/j.pharmr.2026.100132_bib147","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/apt.17719","article-title":"Therapeutic drug monitoring of methotrexate in patients with Crohn\u2019s disease","volume":"58","author":"van de Meeberg","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib148","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100132_bib149","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100132_bib150","article-title":"A novel strategy for treating inflammatory bowel disease by targeting delivery of methotrexate through glucan particles","volume":"9","author":"Sun","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.pharmr.2026.100132_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122741","article-title":"Colon-specific delivery of methotrexate using hyaluronic acid modified pH-responsive nanocarrier for the therapy of colitis in mice","volume":"635","author":"Lv","year":"2023","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100132_bib152","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ad5d9b","article-title":"Codelivery of methotrexate and silibinin by niosome nanoparticles for enhanced chemotherapy of CT26 colon cancer cells","volume":"19","author":"Sharifi-Azad","year":"2024","journal-title":"Biomed Mater"},{"key":"10.1016\/j.pharmr.2026.100132_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.534499","article-title":"Metformin induces apoptosis and inhibits Notch1 in malignant pleural mesothelioma cells","volume":"8","author":"Rossini","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"A","key":"10.1016\/j.pharmr.2026.100132_bib154","article-title":"Codelivery of metformin and methotrexate with optimized chitosan nanoparticles for synergistic triple-negative breast cancer therapy in vivo","volume":"667","author":"Karimian-Shaddel","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharmr.2026.100132_bib155","article-title":"PAMAM dendrimers based co-delivery of methotrexate and berberine for targeting of Hela cancer cells","volume":"13","author":"Majidzadeh","year":"2024","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.pharmr.2026.100132_bib156","article-title":"Methotrexate-loaded Fe-metal organic frameworks: synthesis, characterizations, and drug release investigations","volume":"97","author":"Yunus","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100132_bib157","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41598-025-85702-y","article-title":"An in vitro study of the effects of methotrexate loaded biocomposite beads on MG63 osteoblast cells","volume":"15","author":"Malash","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100132_bib158","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chembiol.2023.09.014","article-title":"Methotrexate-based PROTACs as DHFR-specific chemical probes","volume":"31","author":"Rana","year":"2024","journal-title":"Cell Chem Biol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:42:04Z","timestamp":1779446524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0031699726000207"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100132","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging mechanistic trends and clinical efficacy for methotrexate: Applications to inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100132"}}